40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +1 617 455 4188

The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients.

Discover innovative approaches to surpassing the blood-brain barrier to unlock previously uncovered therapeutic potential, keep ahead of the latest clinical trial design rationale and navigate the regulatory landscape for novel combination therapies with actionable insights to improve clinical success.

With promising clinical readouts from a range of therapeutic modalities, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy, there is more potential than ever before to be unlocked within the GBM space.

To elevate your current standards, join this unique collaboration between industry giants such as Novartis, pioneering biotechs such as Day One Biopharmaceuticals, world-renowned academics and investors. Embrace positive clinical outcomes alongside a dedicated community committed to defeating GBM/CNS tumors and transforming lives.

Access the complete agenda here including a packed pre-workshop conference day, panel discussions, poster sessions and important networking opportunities. Visit www.glioblastoma-drugdevelopment.com for full details.


URLs:
Tickets: https://go.evvnt.com/2034647-2?pid=1052
Brochure: https://go.evvnt.com/2034647-3?pid=1052
Twitter: https://go.evvnt.com/2034647-4?pid=1052

Prices:
Drug Developer - Conference Only: USD 2899.00,
Drug Developer - Conference + 3 Workshops: USD 4097.00,
Academic - Conference Only: USD 2499.00,
Academic - Conference + 3 Workshops: USD 3497.00,
Service Provider - Conference Only: USD 3599.00,
Service Provider - Conference + 3 Workshops: USD 4997.00

Adrienne Boire, Neuro-Oncologist, Memorial Sloan Kettering Cancer Center, Aram Mangasarian, Chief Executive Officer, TME Pharma, Carlo Bertozzi, Chief Executive Officer, Incephalo, Daniela Niepel, Global Radioligand Therapy Early Medical Executive Director, Novartis, David Reardon, Clinical Director and Professor of Medicine, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Francesca Barone, Chief Scientific Officer, Candel Therapeutics, Gregory Stein, Chief Executive Officer, Curtana Pharma, Jing Watnick, Chief Executive Officer, Vigeo Therapeutics, John Bomalaski, Executive Vice-President, Medical Affairs, Polaris Pharmaceuticals, Joohee Sul, Consultant, Sul Clinical, Jorge Benitez-Hernandez, Principal Scientist, Bristol Myers Squibb, Julie Metcalf, Senior Scientist, Fusion Pharmaceuticals, Khalid Shah, Professor, Harvard Medical School, Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society, Kishor Bhatia, Chief Scientific Officer, Lantern Pharma, Mark Exley, Chief Executive Officer, Imvax, Michael Ciesielski, Chief Executive Officer, MimiVax, Michael Lim, Chair, Department of Neurosurgery, Stanford Medicine, Nicholas Butowski, Director of Clinical Services in Neuro-Oncology, University of California San Francisco, Patrick Wen, Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute, Rif Rahman, Assistant Professor in Radiation Oncology, Dana-Farber Cancer Institute, Robert Dillman, Chief Medical Officer, Aivita Biomedical, Robert Shoemaker, Senior Vice President of Research Biology, Erasca, Samuel Blackman, Founder and Head of Research and Development, Day One Biopharmaceuticals, Santosh Kesari, Director of Neuro-Oncology, Professor of Neurosciences/ Chair of Translational Neurosciences, Pacific Neuroscience Institute and Saint John's Cancer, Shannon Morris, Chief Medical Officer, Erasca, Stephen G. Marcus, Chief Executive Officer, Cantex Pharmaceuticals, Timothy Cloughesy, Chief Medical Officer, Global Coalition of Adaptive Research, Trishna Goswami, Chief Medical Officer, In8Bio, Vijay Agarwal, Chief Executive Officer, Alpheus Medical, Zane Yang, Chief Medical Officer, ABM Therapeutics